Galapagos Initiates Phase 1 Trial as Part of its Alliance with Janssen
News Jul 03, 2013
Galapagos NV has announced that it has initiated a First-in-Human (FIH) Phase 1 study with GLPG1205 as part of its alliance with Janssen Pharmaceutica NV.
This achievement triggered a milestone payment of €6.6 million to Galapagos, which will contribute to H1 2013 revenues.
In 2007, Galapagos has announced an alliance agreement with Janssen Pharmaceutica NV providing the option to worldwide, commercial licenses to certain Galapagos internal inflammatory disease programs.
These programs include a novel target for inflammatory disorders that was identified and validated by Galapagos using its proprietary target discovery engine.
Subsequent Galapagos research led to the discovery of GLPG1205, a first-in-class molecule that enters the clinic for inflammatory disorders.
Galapagos will be responsible for execution of Phase 1 and Phase 2A studies with GLPG1205.
"With GLPG1205, Galapagos has moved another proprietary molecule with a novel mode-of-action into the clinic. This program has the potential to unlock a new class of drugs to treat inflammatory disorders. Consistent with our strategy of bringing innovative molecules to the clinic, this is the fourth First-in-Human study with a novel mode-of-action," said Onno van de Stolpe, CEO of Galapagos.
Stolpe continued, "The alliance with Janssen is the second where Galapagos has brought programs from target to the clinic. Today's achievement brings Galapagos' pipeline to five clinical programs, and we are pleased we will be driving the Phase 1 and 2A studies forward with this potential new therapy in inflammatory disease."
The aim of this FIH study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1205.
The randomized, double-blind, placebo-controlled, single center study will be conducted in 40 healthy volunteers in Belgium.
In the first part of the study, single ascending doses will be evaluated. In the second part, the new compound will be administered daily for 14 days. Galapagos expects to disclose topline results from the study by the end of this year.
Agent Reverses Resistance to Targeted Drug in Some LeukemiasNews
After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.READ MORE
Immune Response Restored in Patients with Melanoma Thanks to New CompoundNews
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.READ MORE